bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S4 from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Hernandez-Hoyos Gabriela , Sewell Toddy , Bader Robert , Bannink Jeannette , Chenault Ruth A. , Daugherty Mollie , Dasovich Maria , Fang Hang , Gottschalk Rebecca , Kumer John , Miller Robert E. , Ravikumar Padma , Wiens Jennifer , Algate Paul A. , Bienvenue David , McMahan Catherine J. , Natarajan Sateesh K. , Gross Jane A. , Blankenship John W.
Published: April 2023

Summary of MOR209/ES414 and scFv-scFv Effect on Survival of Mice from C4-2B Xenograft Study
Figure S1 from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors: Hernandez-Hoyos Gabriela , Sewell Toddy , Bader Robert , Bannink Jeannette , Chenault Ruth A. , Daugherty Mollie , Dasovich Maria , Fang Hang , Gottschalk Rebecca , Kumer John , Miller Robert E. , Ravikumar Padma , Wiens Jennifer , Algate Paul A. , Bienvenue David , McMahan Catherine J. , Natarajan Sateesh K. , Gross Jane A. , Blankenship John W.
Published: April 2023

A. Binding of MOR209/ES414 or human IgG1 control on representative CHO cell lines expressing different Fcγ receptors monitored by flow cytometry and plotted as median fluorescence intensity (MFI). B. Cell divisions observed in proliferating CD4+ and CD8+ T cells induced by MOR209/ES414 (0, 1, 10 nM) in the presence of target (C4-2B cells) visualized by loss of CFSE fluorescence. C. T-cell proliferation induced by 1 nM MOR209/ES414 in the presence of C4-2B cells with the number of cell divisions (0-7) indicated.
Sup Figure S5 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood
Authors: Thierry Sylvain , Jdey Wael , Alculumbre Solana , Soumelis Vassili , Noguiez-Hellin Patricia , Dutreix Marie
Published: April 2023

Sup Figure S5. Survival of malignant hematologic and normal human primary immune cells in response to AsiDNA dose escalation in combination with cyclophosphamids (4-HC). (see legend SupFigure-S4)
Movie S1 from ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme
Authors: Cherry Allison E. , Haas Brian R. , Naydenov Alipi V. , Fung Susan , Xu Cong , Swinney Katie , Wagenbach Michael , Freeling Jennifer , Canton David A. , Coy Jonathan , Horne Eric A. , Rickman Barry , Vicente Juan Jesus , Scott John D. , Ho Rodney J.Y. , Liggitt Denny , Wordeman Linda , Stella Nephi
Published: April 2023

T98G cell transfected with GFP-EB3 (green) to label growing MT tips and RFP-CenpB (red) to label centromeres. Speed = 10Ã-.
Supplementary Figure 2 from BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT–Driven Myeloid Leukemia
Authors: Chen Li-Tzong , Chen Chiung-Tong , Jiaang Weir-Torn , Chen Tsai-Yun , Butterfield Joseph H. , Shih Neng-Yao , Hsu John Tsu-An , Lin Hui-You , Lin Sheng-Fung , Tsai Hui-Jen
Published: April 2023

The WST1 assay and IC50 for U937, THP-1, K562, KG-1, and Kasumi-1 cells treated with BPR1J373 for 72 hours
Supplemental tables and figure from Genomic Landscape of Malignant Mesotheliomas
Authors: Kato Shumei , Tomson Brett N. , Buys Timon P.H. , Elkin Sheryl K. , Carter Jennifer L. , Kurzrock Razelle
Published: April 2023

Supplemental Table 1. Baseline characteristics of mesothelioma and frequently associated genomic aberrations; Supplemental Table 2. Patient characteristics and molecular profiling of 42 mesothelioma and examples of cognate targeted therapies; Supplemental Table 3. Association between BAP1 aberrations, subtypes of mesothelioma and co-existing molecular alterations; Supplemental Table 4. Association between NF2 aberration, subtypes of mesothelioma and coexisting molecular alterations; Supplemental Table 5. Association between CDKN2A/B loss, subtypes of mesothelioma and co-existing molecular alterations; Supplemental Table 6: Explanations for the examples of theoretical therapies on Table 1. Supplemental Figure 1.(A) Number of genetic aberrations per patient (B) Number of actionable genetic aberrations per patient either with FDA approved therapies or with therapies that are in clinical trial.
Supplementary figure legends from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies
Authors: Cornet Sébastien , Mathé Doriane , Chettab Kamel , Evesque Anne , Matera Eva-Laure , Trédan Olivier , Dumontet Charles
Published: April 2023

Supplementary figure legends for supplementary figures 1,2 and 3
Supplementary Figure 1 from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies
Authors: Cornet Sébastien , Mathé Doriane , Chettab Kamel , Evesque Anne , Matera Eva-Laure , Trédan Olivier , Dumontet Charles
Published: April 2023

The tumor growth inhibition (TGI) measured on day 56 confirmed the potentiation of trastuzumab antitumor activity when co-injected with pegfilgrastim. Co-treatment with pegfilgrastim and trastuzumab significantly decreased A549 growth when compared to untreated, trastuzumab alone and filgrastim plus trastuzumab groups according to one way ANOVA (p<0,001). In this experiment three mice were used for each group.
Supplementary Figure S2: Expressions of DR5 mRNA and cell-surface DR5 are different between two bladder cancer cell lines. from A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells
Authors: Toriyama Seijiro , Horinaka Mano , Yasuda Shusuke , Taniguchi Tomoyuki , Aono Yuichi , Takamura Toshiya , Morioka Yukako , Miki Tsuneharu , Ukimura Osamu , Sakai Toshiyuki
Published: April 2023

T24 or UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 48 h in T24 cells or 72 h in UM-UC-11 cells. A. Quantitative real-time RT-PCR of DR5 mRNA. The internal control was β2MG. Values show fold change in DR5 expression compared with control (DMSO treatment). Data represent the means of triplicates with SD. B. Cells were stained with PE-labeled mouse anti-human DR5 monoclonal antibody and PE-labeled IgG isotype control. Data were analyzed by flow cytometry. Overlaid histogram is shown in the upper panels. DMSO treatment (gray histogram), OBP-801 treatment (dashed line), celecoxib treatment (dotted line), and combined treatment (solid line). In the lower panels, values show fold change of the geometric mean values in the expression of DR5/IgG. Columns, means of triplicate data; bars, SD; **, P<0.01.
Supplementary Materials and Methods; Supplementary Figures S1-S5; and Supplementary Tables S1-S5 from αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4
Authors: Jin Zhao-Hui , Furukawa Takako , Degardin Mélissa , Sugyo Aya , Tsuji Atsushi B. , Yamasaki Tomoteru , Kawamura Kazunori , Fujibayashi Yasuhisa , Zhang Ming-Rong , Boturyn Didier , Dumy Pascal , Saga Tsuneo
Published: April 2023

The files contain (1) Supplementary Materials and Methods for Î±VÎ²3 expression analysis, autoradiography and histological analysis, and hematology and hepatorenal function; (2) Supplementary Tables S1-S5; and (3) Supplementary Figures S1-S5. Table S1â^'Effects of 37 MBq (1 nmole) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 {plus minus} GF/Lys on hepatorenal functions of U87MG tumor-bearing mice; Table S2â^'Blood cell counts of U87MG tumor-bearing mice at various time points post-injection of 37 MBq (1 nmole) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 {plus minus} GF/Lys; Table S3â^'Blood cell counts of U87MG tumor-bearing mice at various time points after single dose administrations of 37 and 74 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Table S4â^'Effects of 74 MBq (2 nmole) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 + GF/Lys on hepatorenal functions of normal mice; Table S5â^'Human absorbed doses extrapolated from the biodistribution data of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in U87MG tumor-bearing mice; Figure S1â^'The treatment outcomes of radiotherapy with 37 MBq (1 nmole) of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Figure S2â^'Toxicity studies in normal mice that were injected with 74 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Figure S3â^'Preliminary study of U87MG tumors excised at day 13 p.i. of 37 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4 for the changes in microvasculature; Figure S4â^'Positive correlation between the tumor volume and the corresponding WBC in U87MG tumor-bearing mice; Figure S5â^'Biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 at various peptide doses (0.005â^'10 nmole) in U87MG tumor-bearing mice.
Supplementary Table 1 from Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma
Authors: Qin Zhiqiang , Dai Lu , Trillo-Tinoco Jimena , Senkal Can , Wang Wenxue , Reske Tom , Bonstaff Karlie , Del Valle Luis , Rodriguez Paulo , Flemington Erik , Voelkel-Johnson Christina , Smith Charles D. , Ogretmen Besim , Parsons Chris
Published: April 2023

PDF file - 53K, Primer sequences for qRT-PCR in this study.
Supplementary Figure Legend from Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma
Authors: Qin Zhiqiang , Dai Lu , Trillo-Tinoco Jimena , Senkal Can , Wang Wenxue , Reske Tom , Bonstaff Karlie , Del Valle Luis , Rodriguez Paulo , Flemington Erik , Voelkel-Johnson Christina , Smith Charles D. , Ogretmen Besim , Parsons Chris
Published: April 2023

PDF file - 74K
Supplementary Figures S1-S5 from αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4
Authors: Jin Zhao-Hui , Furukawa Takako , Degardin Mélissa , Sugyo Aya , Tsuji Atsushi B. , Yamasaki Tomoteru , Kawamura Kazunori , Fujibayashi Yasuhisa , Zhang Ming-Rong , Boturyn Didier , Dumy Pascal , Saga Tsuneo
Published: April 2023

Figure S1ï€­The treatment outcomes of radiotherapy with 37 MBq (1 nmol) of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Figure S2ï€­Toxicity studies in normal mice that were injected with 74 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Figure S3ï€­Preliminary study of U87MG tumors excised at day 13 p.i. of 37 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4 for the changes in microvasculature; Figure S4ï€­Positive correlation between the tumor volume and the corresponding WBC in U87MG tumor-bearing mice; Figure S5ï€­Biodistribution of 64Cu-cyclam-RAFT-c(-RGDfK-)4 at various peptide doses (0.005ï€­10 nmol) in U87MG tumor-bearing mice.
Supplementary Figure 1 from Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma
Authors: Qin Zhiqiang , Dai Lu , Trillo-Tinoco Jimena , Senkal Can , Wang Wenxue , Reske Tom , Bonstaff Karlie , Del Valle Luis , Rodriguez Paulo , Flemington Erik , Voelkel-Johnson Christina , Smith Charles D. , Ogretmen Besim , Parsons Chris
Published: April 2023

PDF file - 1287K, Lack of drug-associated toxicity for circulating human B cells incubated with ABC294640.
Supplementary Figure S5. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Authors: Patel Hetal , Periyasamy Manikandan , Sava Georgina P. , Bondke Alexander , Slafer Brian W. , Kroll Sebastian H. B. , Barbazanges Marion , Starkey Richard , Ottaviani Silvia , Harrod Alison , Aboagye Eric O. , Buluwela Laki , Fuchter Matthew J. , Barrett Anthony G. M. , Coombes R. Charles , Ali Simak
Published: April 2023

Oral administration of ICEC0942 inhibits cyclin-dependent kinase substrate phosphorylation in mouse peripheral blood mononuclear cells.
Supplementary Figure S3. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Authors: Patel Hetal , Periyasamy Manikandan , Sava Georgina P. , Bondke Alexander , Slafer Brian W. , Kroll Sebastian H. B. , Barbazanges Marion , Starkey Richard , Ottaviani Silvia , Harrod Alison , Aboagye Eric O. , Buluwela Laki , Fuchter Matthew J. , Barrett Anthony G. M. , Coombes R. Charles , Ali Simak
Published: April 2023

Cell Cycle analysis of MCF7 cells treated with ICEC0942.
Figure S3 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Authors: Kizilbash Sani H. , Gupta Shiv K. , Chang Kenneth , Kawashima Ryo , Parrish Karen E. , Carlson Brett L. , Bakken Katrina K. , Mladek Ann C. , Schroeder Mark A. , Decker Paul A. , Kitange Gaspar J. , Shen Yuqiao , Feng Ying , Protter Andrew A. , Elmquist William F. , Sarkaria Jann N.
Published: April 2023

TAL mediated potentiation of TMZ induced DNA damage.
Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Authors: Oberst Michael D. , Augé Catherine , Morris Chad , Kentner Stacy , Mulgrew Kathy , McGlinchey Kelly , Hair James , Hanabuchi Shino , Du Qun , Damschroder Melissa , Feng Hui , Eck Steven , Buss Nicholas , de Haan Lolke , Pierce Andrew J. , Park Haesun , Sylwester Andrew , Axthelm Michael K. , Picker Louis , Morris Nicholas P. , Weinberg Andrew , Hammond Scott A.
Published: April 2023

Supplementary Table 1. Apparent equilibrium binding constants (KD) as determined using flow cytometric methods for binding of MEDI6383 or MEDI6469 to activated human and NHP CD4 T cells or OX40-expressing Jurkat reporter cells, as indicated; Supplementary Table 2. Comparative bioactivity of MEDI6383 and MEDI6469 in 2-cell bioassays using CD32B-expressing HEK cells or Raji B cells for drug clustering and OX40-expressing Jurkat NFKB luciferase reporter cells for activity readout as described in the text; Supplementary Table 3. Affinity/avidity equilibrium binding constants (KD) for MEDI6383 or a human IgG1 version of MEDI6383 where the human IgG4 Fc domains were replaced by human IgG1 Fc domains to human or cyno Fc gamma receptors (FcγR), as indicated.
Supplementary Data from Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy
Authors: Dekhne Aamod S. , Shah Khushbu , Ducker Gregory S. , Katinas Jade M. , Wong-Roushar Jennifer , Nayeen Md. Junayed , Doshi Arpit , Ning Changwen , Bao Xun , Frühauf Josephine , Liu Jenney , Wallace-Povirk Adrianne , O'Connor Carrie , Dzinic Sijana H. , White Kathryn , Kushner Juiwanna , Kim Seongho , Hüttemann Maik , Polin Lisa , Rabinowitz Joshua D. , Li Jing , Hou Zhanjun , Dann Charles E. , Gangjee Aleem , Matherly Larry H.
Published: April 2023

Supplementary Figure S1 shows in vitro antiproliferative activity and targeted pathways of previously reported AICARFTase and GARFTase inhibitors. Supplementary Figure S2 shows docking of AGF291, AGF320, and AGF347 (along with 5-formyl-THF) in human SHMT2 and rabbit SHMT1. Supplementary Figure S3 shows plasma membrane folate transporter expression levels in H460, HCT116, and MIA PaCa-2 human tumor cell lines as compared to those in the IGROV-1 epithelial ovarian cancer cell line. Supplementary Figure S4 shows in vitro antiproliferative activity and targeted pathways of AGF291, AGF320, and AGF347 along with previously reported GARFTase inhibitor AGF94 in H460, HCT116, and MIA PaCa-2 cell lines. Supplementary Figure S5 shows targeted metabolomics data on total serine, serine isotope labeling patterns, total GAR, total AICAR, total adenine nucleotides, and total dTTP along with isotope labeling patterns of H460, HCT116, and MIA PaCa-2 cell lines treated with AGF291, AGF320, and AGF347 not shown in main text Figure 4. Supplementary Figure S6 shows a Western blot confirming knockdown of SHMT2 in H460 SHMT2 KD cell line and knockout of SHMT2 in HCT116 SHMT2 KO cell line. Supplementary Figure S7 shows in vivo efficacies of AGF347 and gemcitabine towards MIA PaCa-2 early and late stage tumor xenograft models where mouse serum folate levels were not depleted to approximate those found in humans. Supplementary Figure S8 shows a cytochrome c oxidase assay on tumors harvested from the metabolomics arm of the late stage in vivo AGF347 trial. Table S1 shows docking scores of novel compounds in human SHMT2 and rabbit SHMT1 (corresponding to Supplementary Figure S2). Table S2 shows quantitative data from in vivo early- and late-stage trials of AGF347 and gemcitabine against MIA PaCa-2 tumor xenografts in NCR SCID mice.
Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Authors: Oberst Michael D. , Augé Catherine , Morris Chad , Kentner Stacy , Mulgrew Kathy , McGlinchey Kelly , Hair James , Hanabuchi Shino , Du Qun , Damschroder Melissa , Feng Hui , Eck Steven , Buss Nicholas , de Haan Lolke , Pierce Andrew J. , Park Haesun , Sylwester Andrew , Axthelm Michael K. , Picker Louis , Morris Nicholas P. , Weinberg Andrew , Hammond Scott A.
Published: April 2023

Supplementary Figure 8. MEDI6383 enhancement of human CD4 T cell proliferation (CFSE dilution) among CD3 enriched T cells. Supplementary Figure 9. Cell surface expression of OX40 and OX40L on A375 melanoma tumor cells and A375-alloreactive human CD4+ T cells. Supplementary Figure 10. Pharmacodynamic effects of MEDI6383 on absolute T and B cell numbers of rhesus monkeys .
Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Authors: Oberst Michael D. , Augé Catherine , Morris Chad , Kentner Stacy , Mulgrew Kathy , McGlinchey Kelly , Hair James , Hanabuchi Shino , Du Qun , Damschroder Melissa , Feng Hui , Eck Steven , Buss Nicholas , de Haan Lolke , Pierce Andrew J. , Park Haesun , Sylwester Andrew , Axthelm Michael K. , Picker Louis , Morris Nicholas P. , Weinberg Andrew , Hammond Scott A.
Published: April 2023

Regulation of cell surface activation markers on CD4 and CD8 T cells by MEDI6383
Supplementary Table 2 from Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies
Authors: Shatsky Rebecca , Parker Barbara A. , Bui Nam Q. , Helsten Teresa , Schwab Richard B. , Boles Sarah G , Kurzrock Razelle
Published: April 2023

This table shows the 68 gene panel (ctDNA).
Supplementary Data from Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition
Authors: Okonska Agata , Bühler Saskja , Rao Vasundhara , Ronner Manuel , Blijlevens Maxime , van der Meulen-Muileman Ida H. , de Menezes Renee X. , Wipplinger Martin , Oehl Kathrin , Smit Egbert F. , Weder Walter , Stahel Rolf A. , Penengo Lorenza , van Beusechem Victor W. , Felley-Bosco Emanuela
Published: April 2023

Supplementary Fig. S1: Characterization of the model used for whole genome silencing, individual screen lethality scores and list of candidate genes with differential lethality scores ; Supplementary Fig. S2: Validation of the RRM1 and RRM2 knockdown; Supplementary Fig. S3: Expression of RRM1 and RRM2 in MPM; Supplementary Fig. S4: Modulation of BAP1 expression, effect on gene expression, response to olaparib, and rescue of gemcitabine cytotoxicity by dNMPs; Supplementary Fig. S5: Schematic representation of the potential role of BAP1 in the regulation of RRM2 on transcriptional level under normal and replicative stress condition; Supplementary Fig. S6: Gemcitabine induced increase of RRM1 and RRM2 in NCI60 cell line panel and high RRM1 and RRM2 expression predicts poor overall survival in malignant pleural mesothelioma patients; Supplementary Table S1: Primer sequences; Supplementary Table S2: Gene ontology analysis on genes with differential lethality score.
Figure S4 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation
Authors: Singh Pankaj K. , Deorukhkar Amit A. , Venkatesulu Bhanu P. , Li Xiaolin , Tailor Ramesh , Bomalaski John S. , Krishnan Sunil
Published: April 2023

BPI colocalization
Supplementary Figure S7 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
Authors: Buondonno Ilaria , Gazzano Elena , Jean Sae Rin , Audrito Valentina , Kopecka Joanna , Fanelli Marilù , Salaroglio Iris C. , Costamagna Costanzo , Roato Ilaria , Mungo Eleonora , Hattinger Claudia M. , Deaglio Silvia , Kelley Shana O. , Serra Massimo , Riganti Chiara
Published: April 2023

Effects of mitochondria-targeted doxorubicin on drug-sensitive osteosarcoma in vivo
Supplementary Figure S4 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma
Authors: Buondonno Ilaria , Gazzano Elena , Jean Sae Rin , Audrito Valentina , Kopecka Joanna , Fanelli Marilù , Salaroglio Iris C. , Costamagna Costanzo , Roato Ilaria , Mungo Eleonora , Hattinger Claudia M. , Deaglio Silvia , Kelley Shana O. , Serra Massimo , Riganti Chiara
Published: April 2023

Effects of mitochondria-targeted doxorubicin in non-transformed osteoblasts and cardiomyocytes
Table S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

Supplementary Table 4: List of cell lines evaluated for sensitivity to SHP099 (Tab 1) or an RTK-inhibitor (Tab 2) in 2D or 3D. Included is the lineage and the KRAS mutation status. Where data are blank, no viable data was available, or the cell line did not grow appropriately as a tumor spheroid.
Table S3 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

Supplementary Table 3: A total of 246 cell lines were evaluated for both SHP2 knockdown and SHP099 sensitivity. Data displays PTPN11 shRNA ATARIS Quantile Score and SHP099 IC50 and Amax for each cell line tested.
Figure S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

(A) Immunoblot of p-RSK3 and qPCR for DUSP6 from MIA PaCa-2 xenografts collected 3 hours after the last dose from Fig 5C. (B) Immunoblot for the designated proteins from MIA PaCa-2 cells grown in 2D, 3D and from in vivo xenografts without compound treatment. Protein loading amount was normalized and verified by tubulin loading control. Each separate column represents an individual treated tumor. (C) Dependency of MET by DRIVE pooled shRNA screen (y axis, ATARIS Quantile score of less than -0.5 indicates a significant effect) and expression of HGF (x-axis) by RNAseq in pancreatic cancer cell lines in CCLE (n=21). (D) Immunoblot of p-RSK3 and qPCR for DUSP6 from KP4 xenografts collected 3 hours after the last dose from Fig 5E. Protein loading amount was normalized and verified by tubulin loading control. Each separate column represents an individual treated tumor (E) Immunoblot for the designated proteins from KP4 cells grown in 2D, 3D and from in vivo xenografts without compound treatment (F) Schematic of RTK-SHP2 signaling highlighting that SHP2 acts downstream of one or more activated RTKs to elicit downstream signaling in KRAS mutant and also additional SHP2-specific, non-MAPK signaling. SHP2 inhibition by SHP099 can serve as a surrogate for cancers where KRAS mutant cancers are dependent on upstream RTKs.
Supplementary Figure S6 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Authors: Moore Heather M. , Savage Heidi M. , O'Brien Carol , Zhou Wei , Sokol Ethan S. , Goldberg Michael E. , Metcalfe Ciara , Friedman Lori S. , Lackner Mark R. , Wilson Timothy R.
Published: April 2023

Supplementary Figure S6: Distribution of PIK3CA and ESR1 mutations in ER+ metastatic breast cancer.
Supplemental Table S1 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
Authors: Hu Shanhu , Lu Yun , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Kawakami Masanori , Sekula David , Compton Duane A. , Freemantle Sarah , Dmitrovsky Ethan
Published: April 2023

The siRNA sequences used in this study.
Supplemenary Figure 2 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Authors: Guichard Sylvie M. , Curwen Jon , Bihani Teeru , D'Cruz Celina M. , Yates James W.T. , Grondine Michael , Howard Zoe , Davies Barry R. , Bigley Graham , Klinowska Teresa , Pike Kurt G. , Pass Martin , Chresta Christine M. , Polanska Urszula M. , McEwen Robert , Delpuech Oona , Green Stephen , Cosulich Sabina C.
Published: April 2023

Pharmacokinetics and PK/PD relationships for AZD2014
Figure S5 from Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
Authors: Shin Dong Hoon , Jo Jeong Yeon , Han Ji-Youn
Published: April 2023

Mouse weight was measured on the final day of the experiment. The weight was not significantly different among groups. Student''s t test, average {plus minus} SEM; n=4~7, *, p<0.05.
Figure S1 from Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
Authors: Shin Dong Hoon , Jo Jeong Yeon , Han Ji-Youn
Published: April 2023

Serum-free media from HEK293T cells transfected with E.V. vector or SLC3A2-NRG1 fusion genes were coated onto 96-well microtiter plates at 10 ï�­g/ml. HEK293T cells transfected with ERBB3 and ERBB4 were seeded, treatment with lapatinib dose dependently, allowed to adhere, and then quickly stained with crystal violet. Student''s t test, average {plus minus} SD; n=4, *, p<0.05.
Supplementary Methods from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Authors: Kietzman William B. , Graham Garrett T. , Ory Virginie , Sharif Ghada M. , Kushner Max H. , Gallanis Gregory T. , Kallakury Bhaskar , Wellstein Anton , Riegel Anna T.
Published: April 2023

Supplementary Methods: Supplementary Table 1 and 2
Supplementary Figures 1-10; Supplemental Tables 1-6; and Supplemental Materials and Methods from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
Authors: Makvandi Mehran , Lee Hwan , Puentes Laura N. , Reilly Sean W. , Rathi Komal S. , Weng Chi-Chang , Chan Ho Sze , Hou Catherine , Raman Pichai , Martinez Daniel , Xu Kuiying , Carlin Sean D. , Greenberg Roger A. , Pawel Bruce R. , Mach Robert H. , Maris John M. , Pryma Daniel A.
Published: April 2023

SI Figure 1: Reaction scheme for synthesizing 1-(4-astatophenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one ([211At]MM4) from tin precursor 1-(4-(tributylstannyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; SI Figure 2: Reverse competitive inhibition curve; SI Figure 3: In vitro screen and dose response curves of cancer cell lines for sensitivity to [211At]MM4; SI Figure 4: Dose response curves for non-radioactive PARP inhibitors in neuroblastoma cell lines; SI Figure 5: Single cell immunofluorescence for PARP-1 and γH2AX in NLF and SK-N-BE(2)-C cell lines after treatment with 37 kBq/mL [211At]MM4 for 1 or 4 h; SI Figure 6: Single cell immunofluorescence for PARP-1 and γH2AX in SK-N-BE2, IMR-05, and SK-N-SY5Y cell lines after treatment with 37 kBq/mL [211At]MM4 for 1, 4, or 24 h; SI Figure 7: Fluorescent western blot for PARP-1, cleaved PARP-1, and γH2AX after treatment with 37 kBq/mL of [211At]MM4 for 1, 4, or 24 h; SI Figure 8: Double strand DNA breaks quantified by measuring phosphorylation of ATM and H2AX after treatment with 37 kBq/mL of [211At]MM4 for 1, 4, or 24 h; SI Figure 9: Cell cycle analysis after treatment with 37 kBq/mL of [211At]MM4 for 1, 4, or 24 h; SI Figure 10: Animal weights from A) single dose efficacy study and B) high dose vs. fractionated therapy; SI Table 1: Cell lines evaluated in this study, their culture media, and relevant mutations; SI Table 2: EC50 values for [211At]MM4 vs. non-targeted radioactive controls; SI Table 3: EC50 values for [211At]MM4 in ovarian cancer cell lines; SI Table 4: EC50 values in molar concentrations for [211At]MM4 vs. non radioactive analogue KX1; SI Table 5: EC50 values for PARP inhibitors in neruoblastoma cell lines; SI Table 6: EC50 values for PARP inhibitors in neruoblastoma cell lines
Supplemental Figure 4 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Authors: Kietzman William B. , Graham Garrett T. , Ory Virginie , Sharif Ghada M. , Kushner Max H. , Gallanis Gregory T. , Kallakury Bhaskar , Wellstein Anton , Riegel Anna T.
Published: April 2023

Palbociclib in the MIND Model
Supplementary Figure 7 from Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells
Authors: Anantharajan Jothi , Zhou Hengbo , Zhang Lingdi , Hotz Taylor , Vincent Melanie Y. , Blevins Melanie A. , Jansson Anna E. , Kuan John Wee Liang , Ng Elizabeth Yihui , Yeo Yee Khoon , Baburajendran Nithya , Lin Grace , Hung Alvin W. , Joy Joma , Patnaik Samarjit , Marugan Juan , Rudra Pratyaydipta , Ghosh Debashis , Hill Jeffrey , Keller Thomas H. , Zhao Rui , Ford Heide L. , Kang CongBao
Published: April 2023

Validation of newly generated Six1 antibody (Ford 1229).
Supplementary Methods from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Authors: Works Melissa , Soni Neha , Hauskins Collin , Sierra Catherine , Baturevych Alex , Jones Jon C. , Curtis Wendy , Carlson Patrick , Johnstone Timothy G. , Kugler David , Hause Ronald J. , Jiang Yue , Wimberly Lindsey , Clouser Christopher R. , Jessup Heidi K. , Sather Blythe , Salmon Ruth A. , Ports Michael O.
Published: April 2023

Supplementary Methods and Figure Legends
Supplementary Table S1 from A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
Authors: Bjørnstad Ronja , Aesoy Reidun , Bruserud Øystein , Brenner Annette K. , Giraud Francis , Dowling Tara Helen , Gausdal Gro , Moreau Pascale , Døskeland Stein Ove , Anizon Fabrice , Herfindal Lars
Published: April 2023

Table showing inhibition of kinases
Supplemental Figure 5 from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

APE1/Ref-1 protein expression affects CA9 mRNA levels in additional PDAC cell lines
Supplemental Figure 1 from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

Structures of APE1/Ref-1 and CA9 inhibitors
Supplementary Table S1 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

Activity of FGF401 in biochemical kinase assays
Fig. S4 from Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease
Authors: Mukherjee Ananda , Patterson Amanda L. , George Jitu W. , Carpenter Tyler J. , Madaj Zachary B. , Hostetter Galen , Risinger John I. , Teixeira Jose M.
Published: April 2023

Supplementary Figure 4. Effects of Zeocin treatment on levels of ï�§H2AX and accumulation of cells in G2/M phase in PTEN-null Ishikawa cells after the overexpression of four different PTEN plasmids. Cells were transfected with plasmids for 24 h, treated with Zeocin for 16 h, then assayed. A-P Levles of ï�§H2AX as determined by co-immunocytostaining with anti-PTEN antibody followed by Alexa Fluor 488 conjugated secondary antibody (green) and anti-phospho H2AX (Ser 139) antibody followed by Alexa Fluor 546 conjugated secondary antibody (red). Nuclei were stained with DAPI (blue). A-D, pEGFP-EV. E-H, PTEN-WT. I-L, PTEN-NLS. M-P, PTEN-NES. Scale bar; 200 Î¼m. Q, Comparison of % ï�§H2AX+ cells as determined by flow cytometry analysis in PTEN transfected cells with or without Zeocin treatment. R, Comparison of the percentage of cells in G2/M as determined by flow cytometry analysis in PTEN transfected cells with or without Zeocin treatment. Statistical analysis performed was paired T-test for each plasmid P<0.05
Fig. S2 from Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease
Authors: Mukherjee Ananda , Patterson Amanda L. , George Jitu W. , Carpenter Tyler J. , Madaj Zachary B. , Hostetter Galen , Risinger John I. , Teixeira Jose M.
Published: April 2023

Supplementary Figure 2. A and B, PTEN immunostaining in adjacent normal tissue (ANT) and EndoCA, respectively. C and D, Immunostaining of phospho-AKT (Ser473) in ANT and EndoCA, respectively. E, TCGA analysis of PTEN expression in human endometrial tumors by high throughput reverse phase protein lysate microarray (RPPA). F-H, PTEN immunostaining of human normal endometrial tissue with the anti-human PTEN antibody generated from three different clones. EG; endometrial gland. Str; stroma.
Supplementary methods from Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin
Authors: Roh Jong-Lyel , Kim Eun Hye , Park Jin Young , Kim Ji Won
Published: April 2023

Supplementary methods
Supplementary Table 2 from R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis
Authors: Guo Yuna , Kenney S. Ray , Muller Carolyn Y. , Adams Sarah , Rutledge Teresa , Romero Elsa , Murray-Krezan Cristina , Prekeris Rytis , Sklar Larry A. , Hudson Laurie G. , Wandinger-Ness Angela
Published: April 2023

Biochemical properties of Cdc42 and Rac1 nucleotide binding
Supplemental Table 1 from Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Authors: Mallery Susan R. , Wang Daren , Santiago Brian , Pei Ping , Bissonnette Caroline , Jayawardena Jayanetti Asiri , Schwendeman Steven P. , Spinney Richard , Lang James
Published: April 2023

Mouse tumor sizes
Supplementary Figure S2 from R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis
Authors: Guo Yuna , Kenney S. Ray , Muller Carolyn Y. , Adams Sarah , Rutledge Teresa , Romero Elsa , Murray-Krezan Cristina , Prekeris Rytis , Sklar Larry A. , Hudson Laurie G. , Wandinger-Ness Angela
Published: April 2023

Cell characterization of primary ovarian cancer cells by immunofluorescence.
Supplemental Figure 3 from Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Authors: Mallery Susan R. , Wang Daren , Santiago Brian , Pei Ping , Bissonnette Caroline , Jayawardena Jayanetti Asiri , Schwendeman Steven P. , Spinney Richard , Lang James
Published: April 2023

Persistence of stem cell phenotype through at least 8 PDL
Supplrementary Table S1 and Supplementary S1-S10 from In Vitro and In Vivo Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer
Authors: Wang Chun-Rong , Mahmood Javed , Zhang Qin-Rong , Vedadi Ali , Warrington Jenny , Ou Ning , Bristow Robert G. , Jaffray David A. , Lu Qing-Bin
Published: April 2023

This file provides supplementary data on in vivo overall radiotoxicity (Table S1), in vitro radiosensitizing effect (Figure S1), histological images (Figures S2, S3, S5-S9) corresponding to the data presented in Figures 4 and 5 in the text, the changes in body weight in healthy and tumor-harboring mice (Figure S4), and additional tumor growth delay curves (Figure S10).
Supplementary Figure S3 from Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
Authors: de Goeij Bart E.C.G. , Vink Tom , ten Napel Hendrik , Breij Esther C.W. , Satijn David , Wubbolts Richard , Miao David , Parren Paul W.H.I.
Published: April 2023

Schematic overview of the mechanism of action of bsHER2xCD63his-ADC
Supplementary Fig. S3 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design
Authors: Lee Nam-Kyung , Su Yang , Bidlingmaier Scott , Liu Bin
Published: April 2023

Surface antigen removal.
Supplementary Figure S9 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S9 shows TIE2 and macrophage markers expression.
Supplementary Table S4 from The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo
Authors: Kim Julie , Wang Chao , de Sabando Ainara Ruiz , Cole Hannah L. , Huang Timothy J. , Yang Jie , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

The estimated tumor volume difference of each dose of SR18662 used in treatment, in comparison to vehicle, in the mouse xenograft model.
Supplementary Figure F2 from Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates
Authors: Malhotra Usha , Mukherjee Sarbajit , Fountzilas Christos , Boland Patrick , Miller Austin , Patnaik Santosh , Attwood Kristopher , Yendamuri Sai , Adjei Araba , Kannisto Eric , Opyrchal Mateusz , Bushunow Peter , Loud Peter , Iyer Renuka , Khushalani Nikhil
Published: April 2023

Supplementary Figure F2 shows expression of micro RNAs by histology
Supplementary Figure F1 from Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates
Authors: Malhotra Usha , Mukherjee Sarbajit , Fountzilas Christos , Boland Patrick , Miller Austin , Patnaik Santosh , Attwood Kristopher , Yendamuri Sai , Adjei Araba , Kannisto Eric , Opyrchal Mateusz , Bushunow Peter , Loud Peter , Iyer Renuka , Khushalani Nikhil
Published: April 2023

Supplementary Figure F1 shows unsupervised hierarchical clustering of 29 cancer cases by their micro RNA expression profile
Supplementary Text from In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma
Authors: Sanchez Ileine M. , Purwin Timothy J. , Chervoneva Inna , Erkes Dan A. , Nguyen Mai Q. , Davies Michael A. , Nathanson Katherine L. , Kemper Kristel , Peeper Daniel S. , Aplin Andrew E.
Published: April 2023

Supplementary Methods and Figure Legends
Figure S4 & S5 from AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Authors: Verma Kshitij , Gupta Nehal , Zang Tianzhu , Wangtrakluldee Phumvadee , Srivastava Sanjay K. , Penning Trevor M. , Trippier Paul C.
Published: April 2023

Supplementary figure S4 & S5: S4: Baccharin does not exert cytotoxicity on prostate cancer cell lines. S5: Percentage cell viability of ENZ at indicated time points across cell lines.
Figure S4 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Authors: Santoro Raffaela , Zanotto Marco , Simionato Francesca , Zecchetto Camilla , Merz Valeria , Cavallini Chiara , Piro Geny , Sabbadini Fabio , Boschi Federico , Scarpa Aldo , Melisi Davide
Published: April 2023

Figure S4 shows: (A) Immunoblot analysis of the indicated cell lines treated with increasing amounts of LiCl for 72h. (B) mRNA expression levels of the indicated genes over β-actin in the indicated cell lines treated with NaCl or LiCl 20mM for 72h. (C) The indicated cell lines were treated with 3μM LY2090314 for 72 hours and cellular extracts were subjected to immunoblot with the indicated antibodies.
Figure S1 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Authors: Santoro Raffaela , Zanotto Marco , Simionato Francesca , Zecchetto Camilla , Merz Valeria , Cavallini Chiara , Piro Geny , Sabbadini Fabio , Boschi Federico , Scarpa Aldo , Melisi Davide
Published: April 2023

Fig.S1 shows: (A) Chemical structure of the indicated compounds. (B) Immunoblot on cellular extracts from cells stably silenced for TAK1 expression. (C) Immunoblot on cellular extracts from cells transiently transfected with the indicated siRNA
Supplementary Figure S1 from Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer
Authors: Ide Hiroki , Inoue Satoshi , Mizushima Taichi , Jiang Guiyang , Chuang Kuang-Hsiang , Oya Mototsugu , Miyamoto Hiroshi
Published: April 2023

The expression and transcriptional activity of AR in bladder cancer sublines.
Supplementary Figure 1 from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach
Authors: Ning Yan , Hanna Diana L. , Zhang Wu , Mendez Angela , Yang Dongyun , El-Khoueiry Rita , Matsusaka Satoshi , Sunakawa Yu , Stremitzer Stefan , Parekh Anish , Okazaki Satoshi , Berger Martin D. , Barzi Afsaneh , Lenz Heinz-Josef
Published: April 2023

ROC curve stratified by combination of CK20 and Survivin gene expression: An optimal cutoff value of either 0.16 for CK20 or 0.15 for Survivin yields a sensitivity of 79.6% and specificity of 85%.
Supplemental Figures 1-6 and Supplemental Tables 1-3 from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
Authors: Li Long-Shan , Reddy Srilakshmi , Lin Zhen-Hua , Liu Shuangping , Park Hyunsil , Chun Stephen G. , Bornmann William G. , Thibodeaux Joel , Yan Jingsheng , Chakrabarti Gaurab , Xie Xian-Jin , Sumer Baran D. , Boothman David A. , Yordy John S.
Published: April 2023

Supplemental Figure 1. Elevated NQO1 expression in patients with HNC correlates with poor overall survival to standard therapy; Supplemental Figure 2. Functional shRNA-NQO1 knockdown rescues β-lapinduced cell death; Supplemental Figure 3. β-Lap-induced NQO1 dependent DNA damage and NAD+ depletion; Supplemental Figure 4. Combination sublethal doses of β-lap and low dose IR induce NQO1 dependent anti-cancer lethality; Supplemental Figure 5. Cooperative antitumor efficacy using a combination of IR and β-lap to treat HNC xenograft models; Figure 6. Expression of Ki-67 after combination of β-lap and IR in HNC xenograft models; Supplemental Table 1. NQO1 enzyme activity and abrogation of activity in 41 HNC cell lines and primary human IMR90 fibroblasts; Supplemental Table 2. Equitoxic doses comparing single to combined treatment in HNC cells; Supplemental Table 3. Individual patient gender, age, subsite, stage, histology and IHC scoring for NQO1 and Catalase
Supplemental Figure S4 from Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome
Authors: Liu Miao , Feng Li-Xing , Sun Peng , Liu Wang , Mi Tian , Lei Min , Wu Wanying , Jiang Baohong , Yang Min , Hu Lihong , Guo De-An , Liu Xuan
Published: April 2023

Western blotting assay of protein expression levels of APOE in Hep3B cells, SMMC-7721, BEL-7402 and SK-HEP-1 cells. Representative results of three independent experiments.
Supplemental Table 2 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Authors: Giulino-Roth Lisa , van Besien Herman J. , Dalton Tanner , Totonchy Jennifer E. , Rodina Anna , Taldone Tony , Bolaender Alexander , Erdjument-Bromage Hediye , Sadek Jouliana , Chadburn Amy , Barth Matthew J. , Dela Cruz Filemon S. , Rainey Allison , Kung Andrew L. , Chiosis Gabriela , Cesarman Ethel
Published: April 2023

IPA analysis of Hps90 client protein networks
Supplemental Figure Legends and Figures 1-7 from The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
Authors: Bid Hemant K. , Phelps Doris A. , Xaio Linlin , Guttridge Denis C. , Lin Jiayuh , London Cheryl , Baker Laurence H. , Mo Xiaokui , Houghton Peter J.
Published: April 2023

Supplemental Figure Legends; Supplemental Figure 1. JQ1 induces G1 accumulation without enhancing the sub-G1 population in sensitive sarcoma cell lines. Cells were exposed for 24 Hr to 500 nM JQ1; Supplemental Figure 2. Quantitation of immunoblots from Figure 1B, and 1C. MYC proteins are normalized against GAPDH; Supplemental Figure 3. JQ1 inhibits angiogenesis in rhabdomyosarcoma xenografts. CD34-positive staining (left panels; magnification 417X) and quantitation of IHC (right panels) for Rh10, and Rh28 rhabdomyosarcoma xenografts after 7 or 14 daily treatments with JQ1 or no treatment (controls); Supplemental Figure 4. JQ1 inhibits angiogenesis in Ewing sarcoma xenografts. CD34- positive staining (left panels; magnification 417X) and quantitation of IHC (right panels) for EW-5 and EW-8 Ewing sarcoma xenografts after 7 or 14 daily treatments with JQ1 or no treatment (controls); Supplemental Figure 5. Summary of JQ1 induced changes in angiogenic factors as determined by angiogenesis arrays in xenografts harvested from mice after 14 days treatment with JQ1, or HUVECs in vitro (0.5 μM 24 hr); Supplemental Figure 6. JQ1 does not inhibit the proliferative compartment in rhabdomyosarcoma xenografts. Ki67-positive staining (left panels; magnification 417X) was quantitated for Rh10, and Rh28 xenografts (right panels; magnification 417X) after 7 or 14 daily treatments with JQ1 or no treatment (controls); Supplemental Figure 7. JQ1 does not inhibit the proliferative compartment in Ewing sarcoma xenografts. Ki67-positive staining (left panels; magnification 417X) was quantitated for EW-5 and EW-8 xenografts (right panels; magnification 417X) after 7 or 14 daily treatments with JQ1 or no treatment (controls).
Supplemental Figure 3 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Authors: Giulino-Roth Lisa , van Besien Herman J. , Dalton Tanner , Totonchy Jennifer E. , Rodina Anna , Taldone Tony , Bolaender Alexander , Erdjument-Bromage Hediye , Sadek Jouliana , Chadburn Amy , Barth Matthew J. , Dela Cruz Filemon S. , Rainey Allison , Kung Andrew L. , Chiosis Gabriela , Cesarman Ethel
Published: April 2023

BL cells but not normal GC B-cells are sensitive to inhibition by PU-H71.